Clinical Trial Search

Primary: Mean Change From Baseline in Schiff Sensitivity Score at Week 8 — -1.47; -0.37 Score on scale — p=0.0001

Primary: The Primary End Point of the Study Was the Mean/Median Number of Days Postsurgery Required for Each Group to Return to 100% Functioning Capacity. — 43; 45 days

Primary: Percentage of Participants With Adverse Events — 96.0; 99.1 percentage of participants with an AE

Primary: Mean Change From Baseline in Work Time Missed Due to Health Problem — 21.0; -18.9 Impairment percentage

Primary: Percentage Change in Wound Area — -39.2; -46.6 percentage change in wound area — p=0.565

Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.0; 72.7; 88.2; 24.4 percentage of segments — p=<0.0001

Primary: Change From Baseline in Weight at Week 52 — 0.25 kg

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Percentage of Assessable Vascular Segments Using Gadobutrol-Enhanced MRA and Unenhanced MRA — 95.9; 77.6; 98.1; 81.7 Percentage of segments — p=<0.000

Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to 8 Hours (AUC[0-8h]) of Vemurafenib on Day 1 — 8.3; 13.8; 21.9; 27.0 micrograms*hour/milliliter (mcg*h/mL)

Primary: Change From Pre-Treatment to 1-week Post Treatment on Brief Pain Inventory-Pain Intensity Scale — 17.52; 14.16; 13.78; 21.18 units on a scale

Primary: Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on…

Primary: Self-Report of Difficulties in Emotion Regulation (DERS) — 101.5; 54.8; 120.5; 56.6 units on a scale — p=<0.004

Primary: Technical Failure Rate — 4.65; 29.44; 1.77; 16.70 percentage of arterial segments

Primary: Overall Survival — 390; 405 Days